LivaNova has applied for the voluntary cancellation of its standard listing of ordinary shares with the United Kingdom Listing Authority and to the London Stock Exchange (LSE), to cancel trading of those shares.
Johns Hopkins Medicine, Baltimore, USA, the Maryland Stem Cell Research Fund (MSCRF) and BioCardia have announced that the first patient has been treated in the pivotal Phase III CardiAmp clinical trial of a cell-based therapy for the treatment of ischemic heart failure that develops after a heart attack.
Only 16% of heart attack survivors get the recommended amount of physical activity in the weeks after hospitalisation, according to a study by researchers at Columbia University Medical Center (CUMC) and NewYork-Presbyterian, both New York City, USA.
Elsevier and the American Society of Echocardiography has announced the launch of Case: Cardiovascular Imaging Case Reports.
The benefits of physical activity may outweigh the impact of overweight and obesity on cardiovascular disease in middle-aged and elderly people, according to research published today in the European Journal of Preventive Cardiology. The observational study was conducted in more than 5,000 people aged 55 years and older who were followed-up for 15 years.
Corindus Vascular Robotics has entered into a Securities Purchase Agreement pursuant to which it will issue and sell an aggregate of 67,941,346 shares of its common stock in a private placement at a purchase price of US$0.6616 per share, resulting in aggregate gross proceeds to the company of approximately US$45,000,000. The closing of the transaction, which is subject to customary closing conditions, is expected to occur on or before March 15, 2017.
Cardiovascular Systems (CSI) has announced the addition of independent board member Martha Goldberg Aronson, an experienced business executive with deep healthcare and medical industry experience.
How are smartphones and computer programs transforming healthcare, especially when it comes to preventing, diagnosing and treating heart disease? This is the focus of a collection of articles recently published in the European Heart Journal.
A new meta-analysis, published in JACC: Cardiovascular Interventions, indicates that RenalGuard (RenalGuard Solutions) significantly reduces the risk of contrast-induced acute kidney injury in high-risk patients undergoing percutaneous coronary intervention (PCI) or transcatheter aortic valve implantation (TAVI). Study authors Alessandro Putzu (Department of Cardiovascular Anesthesia and Intensive Care, Cardiocentro Ticino, Lugano, Switzerland) and others report that lowering the incidence of contrast-induced acute kidney injury could have a strong positive economic impact on healthcare costs.
The FDA has approved a nano-coated coronary stent system—CeloNova Biosciences’ Cobra PzF—for use in percutaneous coronary intervention (PCI), specifically to improve coronary luminal diameter. The approval, a press release reports, is based on the PzF SHIELD clinical trial, which met its primary safety and effectiveness endpoints at 9-month follow-up. The trial showed that the Cobra PzF device was not associated, at this time point, with stent thrombosis and that the rate of clinically-driven target lesion revascularisation was low (4.6%).
A new study published in Catheterization and Cardiovascular Interventions indicates that valve replacement, via surgery or transcatheter aortic valve implantation (TAVI), significantly increases survival at one year compared with balloon valvuloplasty in aortic stenosis patients with end-stage renal disease. It also suggests that there is not an association between duration and type of dialysis and one-year survival.
A network meta-analysis, published in the Journal of the American College of Cardiology, indicates that an off-pump coronary artery bypass grafting (CABG) technique that avoids all manipulation of the ascending aorta—anaortic or “no-touch” off-pump CABG—significantly reduces the risk of postoperative stroke and short-term mortality compared with standard CABG. Another off-pump CABG technique that used the Heartstring clampless system was also found to reduce the risk of stroke compared with standard CABG.
FDA 510(k) clearance has been granted to BTG’s EKOS control unit 4.0. A press release reports that the system includes an ultrasonic device that uses acoustic pulses, powered by the new control unit 4.0, to quickly and safely dissolve blood clots and restore blood flow in patients with pulmonary embolism, deep vein thrombosis, and peripheral arterial occlusions.
In an open public hearing of the FDA’s circulatory system devices panel, according to a press release, nearly all panel members recommended the de novo application of the Sentinel cerebral protection system (Claret Medical) be granted. If the application is granted, the system could become commercially available in the USA. However, a formal vote was not taken as the Sentinel system is a medium-risk accessory device reviewed as a de novo application.
Philips has announced the global launch of Azurion—its next-generation image-guided therapy platform that integrates advanced interventional tools into one clinician platform. Combining advancements in vascular surgery, interventional cardiology, oncology and neuroradiology, Azurion is designed to produce cards that allow clinicians to preprogramme routine tasks and user preferences while an intuitive user interface lets clinicians swiftly and confidently perform a wide range of routine and complex procedures in the interventional lab.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos